CTLA4Ig: bridging the basic immunology with clinical application.
Publication
, Journal Article
Bluestone, JA; St Clair, EW; Turka, LA
Published in: Immunity
March 2006
After a very long and windy road, in December of 2005 the FDA approved CTLA4Ig for the treatment of rheumatoid arthritis. Orencia is the first-in-class antagonist of CD28 costimulation. In this perspective, we discuss the science that led to CTLA4Ig development and the clinical challenges in bringing the drug from the bench to the bedside.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Immunity
DOI
ISSN
1074-7613
Publication Date
March 2006
Volume
24
Issue
3
Start / End Page
233 / 238
Location
United States
Related Subject Headings
- T-Lymphocytes
- Lymphocyte Activation
- Immunology
- Immunoconjugates
- Humans
- CD40 Ligand
- CD28 Antigens
- Animals
- Abatacept
- 3204 Immunology
Citation
APA
Chicago
ICMJE
MLA
NLM
Bluestone, J. A., St Clair, E. W., & Turka, L. A. (2006). CTLA4Ig: bridging the basic immunology with clinical application. Immunity, 24(3), 233–238. https://doi.org/10.1016/j.immuni.2006.03.001
Bluestone, Jeffrey A., E William St Clair, and Laurence A. Turka. “CTLA4Ig: bridging the basic immunology with clinical application.” Immunity 24, no. 3 (March 2006): 233–38. https://doi.org/10.1016/j.immuni.2006.03.001.
Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity. 2006 Mar;24(3):233–8.
Bluestone, Jeffrey A., et al. “CTLA4Ig: bridging the basic immunology with clinical application.” Immunity, vol. 24, no. 3, Mar. 2006, pp. 233–38. Pubmed, doi:10.1016/j.immuni.2006.03.001.
Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity. 2006 Mar;24(3):233–238.
Published In
Immunity
DOI
ISSN
1074-7613
Publication Date
March 2006
Volume
24
Issue
3
Start / End Page
233 / 238
Location
United States
Related Subject Headings
- T-Lymphocytes
- Lymphocyte Activation
- Immunology
- Immunoconjugates
- Humans
- CD40 Ligand
- CD28 Antigens
- Animals
- Abatacept
- 3204 Immunology